L3VLUP
ProSign in

ABT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterABTVRTX
Q3 202027 holders, $24.7bn31 holders, $21.9bn
Q4 202029 holders, $24.8bn30 holders, $18.4bn
Q1 202131 holders, $27.6bn31 holders, $15.4bn
Q2 202129 holders, $26.5bn30 holders, $12.7bn
Q3 202134 holders, $25.4bn35 holders, $10.1bn
Q4 202128 holders, $29.2bn28 holders, $12.4bn
Q1 202234 holders, $24.2bn23 holders, $16.1bn
Q2 202233 holders, $21.5bn25 holders, $18.1bn
Q3 202230 holders, $18.8bn22 holders, $18.4bn
Q4 202225 holders, $20.6bn28 holders, $18.4bn
Q1 202332 holders, $19.2bn26 holders, $21.4bn
Q2 202327 holders, $20.4bn27 holders, $24.7bn
Q3 202330 holders, $17.7bn33 holders, $24.3bn
Q4 202324 holders, $21.0bn32 holders, $28.6bn
Q1 202427 holders, $20.6bn31 holders, $29.8bn
Q2 202437 holders, $16.8bn29 holders, $33.4bn
Q3 202428 holders, $17.7bn27 holders, $33.5bn
Q4 202422 holders, $16.6bn26 holders, $28.5bn
Q1 202528 holders, $20.9bn21 holders, $35.4bn
Q2 202526 holders, $21.1bn21 holders, $32.3bn
Q3 202520 holders, $21.3bn22 holders, $25.9bn
Q4 202525 holders, $20.6bn26 holders, $31.8bn
Q1 202635 holders, $19.1bn25 holders, $31.8bn
Q2 202636 holders, $15.8bn26 holders, $34.6bn
ABT

Abbott Laboratories

Holders
28
Reported value
$20.9bn
Buyers
18
Sellers
11

Breadth +7 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$35.4bn
Buyers
10
Sellers
11

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABT (13)

Acadian Asset Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Dodge & Cox, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Man Group PLC, Polen Capital Management LLC, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd

Only VRTX (6)

ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Hudson Bay Capital Management LP, Marshall Wace LLP, Renaissance Technologies LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →